.png&w=384&q=75)
It is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca*, Citrobacter species*, and Serratia marcescens.
Lower Respiratory Tract Infections, including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens.
Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis*, Serratia marcescens*, and Enterobacter species.
Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species.
Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae*, Pseudomonas aeruginosa, Citrobacter species* including C. freundii*, and Serratia species* including S. marcescens.
Gynecologic Infections, including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae*, Enterobacter species* including E. cloacae*, and Proteus mirabilis.
The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that aztreonam interferes with an autolysin inhibitor.
Urinary tract infections 500 mg or 1 g Frequency (hours) 8 or 12.
Moderately severe systemic infections 1 g or 2 g Frequency (hours) 8 or 12.
Severe systemic or life- threatening infections 2g Frequency (hours) 6 or 8.
Dosage Guidelines for Pediatric Patients:
Mild to moderate infections 30 mg/kg Frequency (hours) 8. Moderate to severe infections 30 mg/kg Frequency (hours) 6 or 8.
Aztreonam has severe interactions with no other drugs. Aztreonam has serious interactions with the following drugs: BCG vaccine live. cholera vaccine
This preparation is contraindicated in patients with known hypersensitivity to Aztreonam or any other component in the formulation.
Common side effects of aztreonam may include:
Limited information indicates that aztreonam produces low levels in milk that are not expected to cause adverse effects in breastfed infants.
Store at 2-8°C for not more than 24 hours.